TrialAmerican journal of hematology2020

Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.

Alex F Herrera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.